April 24, 2026
1 min read

With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms

After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a next-generation multiple myeloma cell therapy later this year.

Leave a Reply

Your email address will not be published.

Previous Story

Student keynote explores pet nutrition career pathways at Petfood Forum

Next Story

Rep. McGovern drafts letter for nutrition, health resources

Previous Story

Student keynote explores pet nutrition career pathways at Petfood Forum

Next Story

Rep. McGovern drafts letter for nutrition, health resources

Latest from Blog

Go toTop